Replies to post #137 on Allergan Plc (AGN)

[DewDiligence]

Adverse ruling on Restasis patent in US District Court:

https://finance.yahoo.com/news/u-district-court-eastern-district-174500864.html

Allergan plc…today acknowledged that the U.S. District Court for the Eastern District of Texas has issued an adverse trial decision finding that the four asserted patents covering RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05% are invalid. The Company will appeal the Court's ruling.

…The patents include United States Patent Nos. 8,629,111; 8,648,048; 8,685,930 and 9,248,191. These patents, along with United States Patent Nos. 8,633,162 and 8,642,556, are listed in the Orange Book for RESTASIS and expire on August 27, 2024.

Unless overturned on appeal, the Districtt Court’s ruling blows up AGN’s patent settlement with PFE (#msg-135360904).